Also found in: Medical.
S1PSphingosine 1-Phosphate
S1PSite-1 Protease
S1PSPH 1-Phosphate
References in periodicals archive ?
Once there, S1P and S2P free SREBP from the membrane so that it can move to the nucleus.
There are 5 S1P receptors, located on lymphocytes, neurons, oligodendrocytes, astrocytes and microglial cells.
acne by exploiting the inherent pharmacological activity of S1P.
Kolesnick of Memorial Sloan-Kettering Cancer Center in New York reported that irradiated female mice pretreated with S1P are fertile and that their offspring and a subsequent generation don't have increased rates of genetic or physical defects.
Finally, the potent capacity of HDL3 to protect endothelial cells from apoptosis may in part reflect HDL3 enrichment in S1P, a minor bioactive lipid (171,179).
Crimean-Congo hemorrhagic fever virus glycoprotein processing by the endoprotease SKI-I/ S1P is critical for virus infectivity.
binds to a docking site (sphingosine-1-phosphate receptor, or S1P receptor) on immune cells that cause nervous system damage in MS.
In this area, Lpath is truly unique, as it appears to be the only company to have developed therapeutically functional monoclonal antibodies against bioactive lipids like S1P and LPA.
In pre-clinical tests, these carriers were found to deliver S1P to
To test their hunch, the scientists injected the ceramide inhibitor S1P into one ovary of each of a group of mice.
Some companies with S1P modulators in development currently are: Novartis, Actelion, Lexicon, Pfizer, Ono Pharmaceuticals, Glaxo Smith Kline, Mitsubishi Tanabe Pharma, Receptos, Arena Pharmaceuticals, Exelixis, Boehringer Ingelheim, Biogen Idec, Kyorin, Angio, Apogee Biotechnology and Lpath.
Ludwig Kappos (Basel, Switzerland) gave a comprehensive overview of the new oral compounds, successful in Phase II trials, that are awaiting confirmation in Phase III trials such as cladribine, teriflunomide, FTY 720 (a modulator of S1P receptors), fumarate, laquinimod, tensirolimus.